Price Chart

Profile

AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
URL http://www.abbvieinvestor.com
Investor Relations URL https://investors.abbvie.com
HQ State/Province Illinois
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Value
Next Earnings Release Oct. 27, 2023 (est.)
Last Earnings Release Jul. 27, 2023
Next Ex-Dividend Date Oct. 12, 2023
Last Ex-Dividend Date Jul. 13, 2023

Profile

AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
URL http://www.abbvieinvestor.com
Investor Relations URL https://investors.abbvie.com
HQ State/Province Illinois
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Value
Next Earnings Release Oct. 27, 2023 (est.)
Last Earnings Release Jul. 27, 2023
Next Ex-Dividend Date Oct. 12, 2023
Last Ex-Dividend Date Jul. 13, 2023